Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 16 systematic review(s)/meta-analysis(es). ^[1-15]
• Rotavirus vaccines, such as RotaTeq and Rotarix, showed a reduction in hospitalizations due to rotavirus gastroenteritis in children under 5, with a median incidence rate ratio of 0.60 (IQR (interquartile range): 0.40-0.87) among unvaccinated children.
• In high-mortality countries, Rotarix and RotaTeq reduced severe rotavirus gastroenteritis cases by 63%-86% in children under 12 months and 54%-86% in children aged 12-23 months.
• Vaccine effectiveness varied by rotavirus genotype, with lower efficacy observed against fully heterotypic genotypes, such as G2P[4].
• In adjusted indirect comparisons, RotaTeq and Rotarix demonstrated similar effectiveness, with Rotarix reducing severe rotavirus gastroenteritis by 93% in low-mortality countries and RotaTeq achieving a 97% reduction.
• No increased risk of serious adverse events, including intussusception, was identified with the use of Rotarix, RotaTeq, Rotasiil, or Rotavac. Additionally, no significant association with autoimmune disorders, such as Type 1 Diabetes or celiac disease, was found in rotavirus-vaccinated populations.
• In high child mortality settings, intussusception risk remained rare and was not significantly higher in vaccinated children compared to those receiving a placebo.
• Rotavirus vaccines demonstrated lower effectiveness in high-mortality settings but maintained significant protection, with higher effectiveness observed in children under 12 months compared to those aged 12-23 months. Effectiveness also varied geographically, being reduced in regions with high genotype diversity, particularly against heterotypic genotypes such as G2P[4].